A subsidiary of the New York Stock Exchange launches trading on Dec. 26 for its first-ever marijuana fund, a major step for an industry that’s struggled to access mainstream U.S. financial instruments, even as Canadian markets have kicked off marijuana investment.
Tag Archives: Biopharmaceutical
GW Pharmaceuticals Plc. is a biopharmaceutical company that discovers, develops, and commercializes cannabinoid prescription medicines. Since May 10, 2013, the stock price has climbed 1,033%.
At the California Cannabis Business Expo on March 8, 2017, entrepreneurs and investors interested in the science and technology of medical cannabis were given a crash course in the future of cannabis, and cannabidiol, as an alternative to pharmaceuticals by Hemp Business Journal founder Sean Murphy.
LONDON, Sept. 7, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference.
COSTA MESA, Calif., and Albany, N.Y., Feb. 8, 2016/ Weed Wire/ —NEMUS Bioscience, Inc. (OTCQB: NMUS) today announced an agreement with Albany Molecular Research Inc. (NASDAQ: AMRI) for the development and manufacture of NEMUS’ proprietary cannabinoid-based active pharmaceutical ingredients.